The FDA Is On A Quest To Rid DTC Drug Ads Of Confounding Fine Print

Forbes: In February, the FDA proposed that pharma companies should no longer be required to run endless pages of fine print describing potential side effects of their drugs in direct-to-consumer (DTC) print ads. Anyone who regularly reads newspapers and magazines has seen what the agency is targeting: the reams of confounding, clinically worded caveats that most people need a magnifying glass to read—and an M.D. or Ph.D. to understand.

Read article

i360Gov Newsletters

The most significant government policy, business, and technology news and analysis delivered to your inbox.

Subscribe Now

Trending